719897
Resomer® RG 502 H, Poly(D,L-lactide-co-glycolide)
acid terminated, viscosity 0.16-0.24 dL/g
Synonym(s):
PLGA
About This Item
Recommended Products
form
amorphous
feed ratio
lactide:glycolide 50:50
degradation timeframe
<3 months
viscosity
0.16-0.24 dL/g
transition temp
Tg 42-46 °C
storage temp.
2-8°C
InChI
1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2
InChI key
LCSKNASZPVZHEG-UHFFFAOYSA-N
Related Categories
Application
- In the formulation ofa non-aqueous drug delivery system for H2S donors to aid thesustained release of the drug.
- To prepare a polymer blend containing Ganciclovir-loaded microspheresdispersed in PLGA–PEG–PLGA polymer gel. This formulation can be used as asustained delivery system for Ganciclovir drug.
Legal Information
related product
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
JAN Code
719897-1G:
719897-BULK:
719897-5G:
719897-VAR:
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Articles
Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.
Synthetic aliphatic polyesters dominate resorbable biomaterials in clinical use.
AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.
Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service